Trinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product Pipeline

Rhea-AI Summary

Trinity Capital (Nasdaq: TRIN) committed $30 million in growth capital to Iantrek to accelerate commercial expansion and advance its bio-interventional ophthalmic surgery product pipeline.

The debt facility will fund commercialization of AlloFlo Uveo, regulatory and development activities, scaling manufacturing and distribution, and market access efforts to broaden physician adoption.

Positive

• Trinity provides $30M growth capital to Iantrek
• Funding targets commercialization of AlloFlo Uveo
• Capital supports regulatory and pipeline development activities
• Supports scaling of manufacturing and distribution capabilities

Negative

• Financing is structured as a debt facility, adding repayment obligations

News Market Reaction – TRIN

+1.70%

+1.70% Session close to close

In the Apr 28 session, TRIN gained 1.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another healthcare-focused growth capital transaction to Trinity Capital’s po...

Analysis

This announcement adds another healthcare-focused growth capital transaction to Trinity Capital’s portfolio, following prior $50 million commitments to Cala Health and Sage Health and steady portfolio activity of $306 million funded in Q1 2026. The $30 million facility to Iantrek underscores Trinity’s role in scaling innovative medical technologies. Investors may watch upcoming earnings on May 6, 2026, dividend declarations, and further deal flow to gauge the sustainability and risk profile of this deployment pace.

Key Figures

Growth capital commitment: $30 million

1 metrics

Growth capital commitment $30 million Debt growth capital provided by Trinity Capital to Iantrek

Historical Context

5 past events · Latest: Apr 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Growth capital deal	Positive	+0.3%	Committed $50M in growth capital to Cala Health for commercial expansion.
Apr 10	Portfolio activity update	Positive	+0.2%	Reported Q1 2026 activity with $306M funded and $395M of new commitments.
Apr 08	Earnings call scheduling	Neutral	+0.4%	Announced timing of Q1 2026 financial results release and conference call.
Mar 27	Growth capital deal	Positive	-0.6%	Provided $50M debt term loan to Sage Health to expand wellness centers.
Mar 18	Dividend declaration	Positive	+0.6%	Declared monthly $0.17 per share cash distributions for Q2 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent business updates and capital deployment headlines have generally coincided with modestly positive next‑day moves, with one divergence on a prior $50M growth capital announcement.

Recent Company History

Over the past months, Trinity Capital has highlighted steady capital deployment and shareholder returns. It committed $50 million to Cala Health on Apr 20, 2026 and another $50 million debt term loan to Sage Health on Mar 27, 2026, alongside Q1 2026 portfolio activity of $306 million funded and $395 million in new commitments on Apr 10, 2026. A recurring $0.17 monthly dividend for Q2 2026 underscores income focus. Today’s Iantrek growth capital fits this pattern of scaling healthcare exposure through debt financing.

Key Terms

bio-interventional ophthalmic surgery (BIOS), glaucoma, ocular pressure, micro-interventional procedures

4 terms

bio-interventional ophthalmic surgery (BIOS) medical

"a leader in the bio-interventional ophthalmic surgery (BIOS) space."

Bio-interventional ophthalmic surgery (BIOS) covers eye procedures that combine precise physical techniques with living therapies—such as cell-based treatments, biological implants, or targeted drug delivery—to repair or restore vision. Investors should watch BIOS because it blends surgical devices and biologic medicines, creating opportunities for higher-priced, differentiated treatments but also carrying complex development, regulatory and reimbursement risks similar to both drugs and medical devices; think of it as a hybrid product that can command premium returns if it proves safe and effective.

glaucoma medical

"designed to treat chronic eye diseases, particularly glaucoma, aimed at restoring"

Glaucoma is a group of eye diseases that slowly damage the optic nerve, often because fluid buildup raises pressure inside the eye, and can lead to permanent vision loss if untreated. For investors, glaucoma matters because it creates sustained demand for medications, surgical devices, diagnostics and follow-up care; breakthroughs or approvals can drive sales and market value much like fixing a clogged drain prevents damage to a house’s wiring.

ocular pressure medical

"restoring the eye's natural fluid outflow pathways and reducing ocular pressure."

Ocular pressure is the internal pressure inside the eyeball created by the balance of fluid produced and drained within the eye, similar to how the tightness of a balloon depends on how much air it holds. It matters to investors because sustained abnormal pressure is a key sign of eye diseases such as glaucoma, driving demand for medications, surgical devices, diagnostic tools and regulatory decisions that can significantly affect the revenues and prospects of healthcare and medical-device companies.

micro-interventional procedures medical

"solutions that seek to help enable micro-interventional procedures for improved"

Micro-interventional procedures are minimally invasive medical treatments that use very small instruments, catheters or implants guided by imaging to target a specific problem inside the body, similar to fixing wiring through a small access hole rather than tearing open a wall. They matter to investors because they drive demand for specialized devices, procedure-related revenue and recurring consumables, and their adoption, regulatory approval and insurance coverage can significantly affect a medical device or healthcare company’s growth and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHOENIX, April 28, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading international alternative asset manager, today announced the commitment of $30 million in growth capital to Iantrek, a medical technology company and a leader in the bio-interventional ophthalmic surgery (BIOS) space.

Iantrek develops minimally invasive surgical technologies designed to treat chronic eye diseases, particularly glaucoma, aimed at restoring the eye's natural fluid outflow pathways and reducing ocular pressure. Its technology includes instrumentation and biologic tissue solutions that seek to help enable micro-interventional procedures for improved patient outcomes.

"We believe Iantrek's innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are pleased to support their team as they enter this next phase of rapid growth."

This debt facility follows a successful series C raise in 2025 which closed in 2025 and included lead equity investors USVP, Sectoral, aMoon, and Visionary Ventures. Trinity's growth capital will support Iantrek in accelerating commercial expansion of its product portfolio, advancing development and regulatory activities for pipeline products, scaling manufacturing and distribution capabilities, and strengthening market access initiatives to broaden physician and patient adoption.

"This financing is a strategic step to keep pace with growing physician demand for our platform. It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology, and advance the next wave of bio-interventional innovation," said Adam Szaronos, Chief Executive Officer of Iantrek.

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn.

About Iantrek
Iantrek, Inc. (www.iantrekmed.com) is a leader in bio-interventional ophthalmic surgery (BIOS), developing a portfolio of surgical technologies designed to restore natural ocular outflow pathways through biologic reinforcement rather than bypass or tissue removal. With the launch of AlloFlo Uveo in October 2025 and the U.S. introduction of AlloSpan Canal, Iantrek will be the only organization offering complementary surgical solutions targeting both natural outflow pathways—enabling a more comprehensive and physiologic approach to glaucoma intervention over the course of the disease. For more information, visit iantrekmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-30-million-in-growth-capital-to-iantrek-to-accelerate-commercial-expansion-and-advance-product-pipeline-302755098.html

SOURCE Trinity Capital Inc.

FAQ

What did Trinity Capital (TRIN) announce about Iantrek on April 28, 2026?

Trinity committed $30 million in growth capital to Iantrek. According to the company, the debt facility will accelerate commercialization, advance pipeline regulatory work, and scale manufacturing and distribution for Iantrek's ophthalmic technologies.

How will the $30 million from TRIN be used by Iantrek?

The financing will fund commercial expansion and product advancement. According to Iantrek, proceeds target accelerating AlloFlo Uveo adoption, advancing development and regulatory activities, and expanding manufacturing, distribution, and market access.

Is Trinity's investment in Iantrek equity or debt for TRIN shareholders?

Trinity's commitment is provided as a debt facility. According to the announcement, the structure is a loan-style growth capital facility rather than a new equity stake disclosure.

What product does Iantrek plan to accelerate with TRIN's $30M funding?

Iantrek will accelerate adoption of AlloFlo Uveo, its lead commercial technology. According to Iantrek, the funding is intended to boost physician uptake and commercial expansion for that platform.

Which investors previously supported Iantrek before Trinity's financing?

Iantrek completed a Series C in 2025 with lead equity investors including USVP, Sectoral, aMoon, and Visionary Ventures. According to the company, Trinity's facility follows that Series C raise.